S&P 500   3,280.43 (-0.02%)
DOW   27,055.92 (-0.34%)
QQQ   268.11 (+0.22%)
AAPL   110.28 (+0.18%)
MSFT   203.29 (+0.37%)
FB   249.40 (+0.50%)
GOOGL   1,442.60 (+0.87%)
AMZN   3,043.96 (+2.82%)
NVDA   488.66 (-2.40%)
TSLA   425.69 (-5.27%)
BABA   271.31 (-0.92%)
CGC   15.57 (-1.08%)
GE   6.27 (-1.26%)
MU   49.02 (-0.26%)
AMD   75.52 (-3.10%)
T   28.66 (+0.10%)
F   6.81 (-0.87%)
ACB   6.45 (+2.06%)
GILD   63.56 (-1.01%)
NFLX   484.30 (-0.63%)
DIS   125.71 (+0.24%)
BAC   24.14 (-1.35%)
BA   155.78 (-0.36%)
S&P 500   3,280.43 (-0.02%)
DOW   27,055.92 (-0.34%)
QQQ   268.11 (+0.22%)
AAPL   110.28 (+0.18%)
MSFT   203.29 (+0.37%)
FB   249.40 (+0.50%)
GOOGL   1,442.60 (+0.87%)
AMZN   3,043.96 (+2.82%)
NVDA   488.66 (-2.40%)
TSLA   425.69 (-5.27%)
BABA   271.31 (-0.92%)
CGC   15.57 (-1.08%)
GE   6.27 (-1.26%)
MU   49.02 (-0.26%)
AMD   75.52 (-3.10%)
T   28.66 (+0.10%)
F   6.81 (-0.87%)
ACB   6.45 (+2.06%)
GILD   63.56 (-1.01%)
NFLX   484.30 (-0.63%)
DIS   125.71 (+0.24%)
BAC   24.14 (-1.35%)
BA   155.78 (-0.36%)
S&P 500   3,280.43 (-0.02%)
DOW   27,055.92 (-0.34%)
QQQ   268.11 (+0.22%)
AAPL   110.28 (+0.18%)
MSFT   203.29 (+0.37%)
FB   249.40 (+0.50%)
GOOGL   1,442.60 (+0.87%)
AMZN   3,043.96 (+2.82%)
NVDA   488.66 (-2.40%)
TSLA   425.69 (-5.27%)
BABA   271.31 (-0.92%)
CGC   15.57 (-1.08%)
GE   6.27 (-1.26%)
MU   49.02 (-0.26%)
AMD   75.52 (-3.10%)
T   28.66 (+0.10%)
F   6.81 (-0.87%)
ACB   6.45 (+2.06%)
GILD   63.56 (-1.01%)
NFLX   484.30 (-0.63%)
DIS   125.71 (+0.24%)
BAC   24.14 (-1.35%)
BA   155.78 (-0.36%)
S&P 500   3,280.43 (-0.02%)
DOW   27,055.92 (-0.34%)
QQQ   268.11 (+0.22%)
AAPL   110.28 (+0.18%)
MSFT   203.29 (+0.37%)
FB   249.40 (+0.50%)
GOOGL   1,442.60 (+0.87%)
AMZN   3,043.96 (+2.82%)
NVDA   488.66 (-2.40%)
TSLA   425.69 (-5.27%)
BABA   271.31 (-0.92%)
CGC   15.57 (-1.08%)
GE   6.27 (-1.26%)
MU   49.02 (-0.26%)
AMD   75.52 (-3.10%)
T   28.66 (+0.10%)
F   6.81 (-0.87%)
ACB   6.45 (+2.06%)
GILD   63.56 (-1.01%)
NFLX   484.30 (-0.63%)
DIS   125.71 (+0.24%)
BAC   24.14 (-1.35%)
BA   155.78 (-0.36%)
Log in
NASDAQ:IDXX

IDEXX Laboratories Stock Forecast, Price & News

$364.72
+0.02 (+0.01 %)
(As of 09/22/2020 10:41 AM ET)
Add
Compare
Today's Range
$359.29
Now: $364.72
$366.10
50-Day Range
$354.20
MA: $378.30
$406.31
52-Week Range
$168.65
Now: $364.72
$407.86
Volume3,145 shs
Average Volume576,893 shs
Market Capitalization$31.02 billion
P/E Ratio68.95
Dividend YieldN/A
Beta0.81
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Read More
IDEXX Laboratories logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.21 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.41 billion
Cash Flow$6.00 per share
Book Value$2.07 per share

Profitability

Net Income$427.72 million

Miscellaneous

Employees9,200
Market Cap$31.02 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$364.72
+0.02 (+0.01 %)
(As of 09/22/2020 10:41 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

How has IDEXX Laboratories' stock been impacted by COVID-19?

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IDXX shares have increased by 48.6% and is now trading at $364.92.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of IDEXX Laboratories?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IDEXX Laboratories
.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for IDEXX Laboratories
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings data on Friday, July, 31st. The company reported $1.72 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.17 by $0.55. The business had revenue of $637.20 million for the quarter, compared to analysts' expectations of $589.98 million. IDEXX Laboratories had a net margin of 18.59% and a return on equity of 241.52%. The business's quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter last year, the company earned $1.43 EPS.
View IDEXX Laboratories' earnings history
.

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories declared that its board has authorized a stock repurchase plan on Wednesday, February 12th 2020, which permits the company to repurchase 5,000,000 shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its stock is undervalued.

What price target have analysts set for IDXX?

4 brokerages have issued 12 month target prices for IDEXX Laboratories' stock. Their forecasts range from $310.00 to $422.00. On average, they expect IDEXX Laboratories' stock price to reach $374.25 in the next year. This suggests a possible upside of 2.6% from the stock's current price.
View analysts' price targets for IDEXX Laboratories
.

Who are some of IDEXX Laboratories' key competitors?

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), Paypal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Shopify (SHOP), Trade Desk (TTD) and Walt Disney (DIS).

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:
  • Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)
  • Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Corp. Sec. (Age 60)
  • Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)
  • Mr. Jay Mazelsky, Exec. VP of Companion Animal Group (Age 58)

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.08%), BlackRock Inc. (8.82%), Bamco Inc. NY (4.04%), Blair William & Co. IL (1.82%), Principal Financial Group Inc. (1.46%) and Neuberger Berman Group LLC (1.33%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, James F Polewaczyk, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends for IDEXX Laboratories
.

Which major investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., CIBC Private Wealth Group LLC, Vanguard Group Inc., Two Sigma Advisers LP, FMR LLC, Man Group plc, Bamco Inc. NY, and Bank of Montreal Can. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan W Ayers, M Anne Szostak, Nimrata Hunt, and Rebecca M Henderson.
View insider buying and selling activity for IDEXX Laboratories
.

Which major investors are buying IDEXX Laboratories stock?

IDXX stock was bought by a variety of institutional investors in the last quarter, including WCM Investment Management LLC, First Trust Advisors LP, AMF Pensionsforsakring AB, Frontier Capital Management Co. LLC, Capital Investment Services of America Inc., Envestnet Asset Management Inc., Bellevue Group AG, and Natixis Advisors L.P..
View insider buying and selling activity for IDEXX Laboratories
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $364.92.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $31.04 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 9,200 workers across the globe.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is www.idexx.com.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.